Treatment
Adc clinical trials
We’re tracking 63 recruiting studies that include Adc, each written for real people, not researchers, below.
Recruiting studies
- NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT06851299RecruitingPhase 2
Trop2-ADC alone or with immunotherapy for advanced triple-negative breast cancer
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18–70 - NCT05403242RecruitingPhase 1/Phase 2
Study drug RC48-ADC plus S-1 for advanced HER2 stomach cancers
This Phase 1/2 study tests RC48-ADC (an antibody-drug treatment) together with S-1 (a chemotherapy medicine) in people with advanced stomach or esophagus/gastroesophageal junction cancer. It’s mainly for cancers with HER2 testing results of IHC 2+ and FISH-negative, and aims to find a safe dose and how well the treatment works as a first treatment option.
BeijingAges 18 years+ - NCT07362888RecruitingPhase 1
Testing a new drug ADCE-B05 for advanced solid tumors
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Springdale, ArkansasAges 18 years+ - NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Rogers, ArkansasAges 18 years+ - NCT05302284RecruitingPhase 3
Testing RC48-ADC plus toripalimab for first-time urothelial cancer
This trial tests whether RC48-ADC combined with toripalimab works better as the first treatment for urothelial cancer that cannot be removed by surgery or has spread. It may help shrink tumors and improve outcomes in people whose cancer has the right HER2 and other eligibility features.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05917158RecruitingPhase 2
HER2-targeted drug study after kidney/ureter tumor surgery
This Phase 2 trial studies a HER2-targeted medicine (RC48-ADC) plus another drug (JS001) to help prevent cancer from coming back after surgery for upper urinary tract urothelial cancer. It may be an option if your tumor has higher HER2 levels and you have no spread to distant organs.
Nanjing, JiangsuAges 18 years+ - NCT05943379RecruitingPhase 2
RC48 antibody plus gemcitabine for high-risk bladder cancer
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06145308RecruitingPhase 2
Precision treatment for salivary gland cancer
This trial tests a personalized treatment approach for recurrent or metastatic salivary gland cancer. It uses special tests on your tumor to find the best targeted therapy for your specific cancer type.
Beijing, Beijing MunicipalityAges 18–100 - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06793332RecruitingPhase 2
Ivonescimab and Trodelvy for breast cancer with brain metastases
This trial tests two drugs (Ivonescimab and a Trop2 ADC) for people with triple-negative breast cancer that has spread to the brain. It aims to see if this combination can shrink brain tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06797999RecruitingPhase 1/Phase 2
Study of ADCE-D01 for soft tissue sarcoma
This trial tests a new drug called ADCE-D01 for people with soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if it is safe and effective.
Aurora, ColoradoAges 18 years+ - NCT06878625RecruitingPhase 2
Trop-2 drug combo for advanced triple-negative breast cancer
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07610616Recruiting
Testing ADC Drug Effectiveness Using Lung Cancer Lab Models
This research study tests how a lung cancer drug called Trastuzumab deruxtecan (T-DXd) works by growing your cancer cells in a lab dish and studying them with your immune cells. The goal is to better understand which patients might benefit most from this treatment.
Guangzhou, GuangdongAges 18–100 - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Orlando, FloridaAges 18 years+ - NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT06303505RecruitingPhase 1/Phase 2
Study of TUB-040 for ovarian and lung cancer
This study tests a new drug called TUB-040 that targets a protein (NaPi2b) found on some ovarian and lung cancer cells. It is for people whose cancer has stopped responding to standard treatments and who have not had certain lung problems in the past.
Birmingham, AlabamaAges 18 years+ - NCT06548529Recruiting
HER2 PET/CT scan to predict treatment response in bladder cancer
This trial uses a special PET/CT scan to see if your bladder cancer has HER2 proteins, which can help predict how well you will respond to a targeted antibody-drug conjugate treatment. It is for people with advanced bladder cancer who have already tried certain standard therapies.
BeijingAges 18–80 - NCT05205850RecruitingPhase 1/Phase 2
RC118 for solid cancers with Claudin 18.2 on tumor cells
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT06959108RecruitingPhase 2
Comparing two treatments for head and neck cancer before chemoradiation
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
VillejuifAges 18–75 - NCT07151898Recruiting
PET/CT scan to see if a new drug is working in advanced lung cancer
This trial tests whether a special PET/CT scan can show how well a Trop2-targeting drug is working in people with advanced lung cancer that has already been treated. It aims to improve how we monitor treatment response.
Xiamen, FujianAges 18 years+ - NCT06883487Recruiting
Exploring HER2 testing in high-grade ovarian cancer
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
Guangzhou, GuangdongAges 18–75
What Adc is being studied for
Conditions with recruiting Adc studies.
Common questions
- Are there clinical trials studying Adc?
- Yes. Clin2 currently lists 63 recruiting studies that include Adc, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adc trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adc an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adc or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.